Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer
Jeremy B. Foote, Sujith Sarvesh, Sameer Al Diffalha, David K. Crossman, Changde Cheng, Myung-Hee Kim, Cherlene Hardy, Julienne L. Carstens, Kyoko Kojima, Bart J. Rose, Christopher A. Klug
Jeremy B. Foote, Sujith Sarvesh, Sameer Al Diffalha, David K. Crossman, Changde Cheng, Myung-Hee Kim, Cherlene Hardy, Julienne L. Carstens, Kyoko Kojima, Bart J. Rose, Christopher A. Klug
View: Text | PDF
Research Article Gastroenterology Immunology Oncology

Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer

  • Text
  • PDF
Abstract

Antibody production by B cells has emerged as an important factor in regulating antitumor immunity with both suppressive and promotive roles in cancer. However, the specific effect of antibody deficiency during development of pancreatic ductal adenocarcinoma (PDAC) has not been explored. To address this question, we crossed the well-established KPC mouse model to mice lacking all circulating immunoglobulin (Ig) due to genetic ablation of both Ig secretion and Ig class switching (KPC-μSAID mice). KPC-μSAID mice exhibited a two-fold acceleration in tumor formation, a two-fold reduction in median survival, and increased liver metastases versus KPC-WT control mice. Immunofluorescence analysis of pancreatic tissues from antibody-sufficient KC- and KPC-WT mice showed that IgG was predominantly localized within the extracellular matrix (ECM). Furthermore, in both KC- and KPC-μSAID mice, ECM density and podoplanin+ cancer-associated fibroblasts (CAFs) were significantly reduced. In the KPC-μSAID tumor microenvironment (TME), intratumoral myeloid-derived suppressor cells (MDSC) were also increased, while CD4+ and CD8+ T cells decreased, relative to tumor-bearing KPC-WT mice, with macrophage exhibiting a mixed polarization phenotype. These findings were recapitulated in antibody subclass–deficient, KPC-AID mice, suggesting a potentially novel function of IgG in suppressing PDAC progression by directly or indirectly regulating pancreatic fibrosis and the density of the ECM.

Authors

Jeremy B. Foote, Sujith Sarvesh, Sameer Al Diffalha, David K. Crossman, Changde Cheng, Myung-Hee Kim, Cherlene Hardy, Julienne L. Carstens, Kyoko Kojima, Bart J. Rose, Christopher A. Klug

×

Figure 1

Antibody deficiency accelerates tumorigenesis in the KC and KPC models of pancreatic cancer.

Options: View larger image (or click on image) Download as PowerPoint
Antibody deficiency accelerates tumorigenesis in the KC and KPC models o...
(A) Representative H&E images of various stages of preinvasive neoplasia, 400X magnification. (B) The proportion of normal, acinar-to-ductal metaplasia (ADM), mPanIn1, mPanIn2, and mPanIn3 ducts were assessed in 5-month-old Pdx1-Cre, KC-WT, and KC-μSAID mice by blinded assessment, n = 10–34 mice/genotype, *P < 0.05, ****P < 0.0001; 2-way ANOVA with Šídák’s multiple-comparison test. (C) Kaplan-Meier survival curve of KPC-WT, KPC-μSAID, and Pdx1-Cre;Tp53FL/+ WT control mice, n = 23–31 mice/genotype. ***P < 0.001; log rank test. (D) The proportion of normal, acinar-to-ductal metaplasia (ADM), mPanIn1, mPanIn2, and mPanIn3 ducts were assessed in 5-month-old Pdx1-Cre, KPC-WT and KPC-μSAID mice by blinded assessment, n = 37–52 mice/genotype, ****P < 0.0001; 2-way ANOVA with Šídák’s multiple-comparison test. (E) Representative gross image of a pancreatic tumor (left panel, top) that exhibited a well-differentiated phenotype (left panel, bottom). Incidence of PDAC in 12-week-old Pdx1-Cre;Tp53FL/+ control, KPC-WT, and KPC-μSAID mice was based on analysis of H&E-stained pancreatic tissue sections, n = 10–63 mice/genotype, mean ± SEM, ***P < 0.001; Welch’s t test. (F) Stacked bar graphs depicting extent of tumor progression in 12-week-old Pdx1-Cre;Tp53FL/+ WT control, KPC-WT, and KPC-μSAID mice based on a blinded assessment of the abundance of normal, premalignant (ADM + mPanIn1-3), or locally invasive malignant cells, H&E 40x + 20x, n = 30–61 mice/genotype, ***P < 0.001, ****P < 0.0001; mean ± SEM. Two-way ANOVA with Tukey’s multiple-comparison test. (G) Left panel: Mitotic figures (arrow) in 10, 40x fields. Right panel: number of mitotic figures were summed from 10 (40×) high-power fields. *P < 0.05; Welch’s t test. (H) Enhanced liver metastases in KPC-μSAID mice. Left panel: H&E-stained image of lung and liver with intralesional tumor cells (red asterisk) consistent with microscopic metastases (40X). Right panel: Proportions of mice exhibiting microscopic evidence of lung and liver metastases in 12-week-old Pdx1-Cre;Tp53FL/+ (n = 10), KPC-WT (n = 18), and KPC-μSAID mice (n = 18) mice. The number mice/lesion is shown as a percentage.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts